




Curing Cancer, Saving Lives 治癒癌症，拯救生命

Asian Fund for Cancer Research 亞洲癌症研究基金會


MISSION STATEMENT 我們的使命

The Asian Fund for Cancer Research Limited (AFCR) is a non-profit organization committed to curing cancers that have significant impacts on the Asian populations. Headquartered in Hong Kong, AFCR is uniquely positioned to implement in Asia the newest cancer research discoveries and technologies from around the world, investigate the distinct causes of cancer in Asian populations through innovative genetic and molecular research, and develop more effective therapies tailored to Asian cancer patients. AFCR is dedicated to bridging the scientific and educational gaps in cancer research and cancer prevention between Asian countries and the rest of the world through promoting, coordinating and funding international collaboration in cancer research and public education. We are fully devoted to reducing the incidence and increasing the survival rate of cancers in Asia.

亞洲癌症研究基金會是一家致力於研究治癒亞洲高發癌症的公益組織。立足於香港，亞洲癌症研究基金會以其獨特的定位，將世界各地癌症研究的最新技術成果積極應用於亞洲的癌症科研領域，運用創新性遺傳和分子生物學技術來探求亞洲人群罹患癌症的特殊原因，並力求開發針對亞洲癌症患者更為有效的治療方法。亞洲癌症研究基金會將通過促進、協調和資助癌症研究和公眾教育方面的國際合作，來縮短亞洲國家同世界其他地區在癌症研究和癌症預防教育領域的差距。我們的目標是降低亞洲地區癌症發病率並提高癌症患者的生存率。

TABLE OF CONTENTS 目錄

Our Unique Approach.....	1-2
Research Program Overview.....	3-6
International Partnerships on Cancer Research.....	7-10
Research Discoveries.....	11-12
Fostering International Research Collaboration.....	13-14
A Fight against Cancer that's Beyond Personal.....	15-16
Public Education on Cancer.....	17-20
我們的獨特性.....	1-2
科研項目概述.....	3-6
國際合作科研項目概述.....	7-10
重要科研成果概述.....	11-12
促進國際科研合作.....	13-14
行動起來，共抗癌症.....	15-16
癌症公眾教育.....	17-20



OUR UNIQUE APPROACH

While other cancer charities focus on different works such as patient care, AFCR aims at advancing cutting-edge cancer research, building an international network, creating research collaborative platforms, as well as promoting public awareness to defeat cancer.

Advancing Cutting-Edge Cancer Research

We believe that research holds the key to curing cancer. That's why at AFCR, we place the highest priority in advancing leading-edge cancer research in all important fields that will lead to better preventative methods, advanced diagnostic tools, more effective treatment approaches, and ultimately, cures for all cancers.

Building an International Network


Through working with an international network of leading cancer scientists, top cancer research hospitals and institutions, and international biopharmaceutical companies, AFCR is uniquely positioned to gather top research minds across the globe to investigate the distinct causes of cancer in Asian populations through innovative genetic and molecular research, and implement in Asia the newest cancer research discoveries and technologies available elsewhere.

Creating Collaborative Platforms

AFCR is working to establish a number of collaborative platforms for our researchers. By fostering frequent interactions among our outstanding scientists, resources can be most effectively leveraged, and discoveries can be more quickly translated into new clinical practices that benefit cancer patients.

Promoting Public Awareness of Cancer

AFCR provides the public with a wide variety of in-depth, up-to-date cancer prevention information and healthy lifestyle tips. We help the community understand the latest scientific achievements and their potential significance to improve the prevention, diagnosis and treatment of cancer. Armed with this knowledge, people can better protect themselves against cancer.



我們的獨特性

很多癌症公益組織的工作重點放在為癌症患者提供醫療及護理方面服務上，AFCR則側重於推進尖端癌症研究，拓展國際科研網絡，構建合作平台，以及增進公眾的防癌抗癌意識。

推進尖端癌症研究

我們深信科研是尋求癒癌良方的關鍵。因此，我們的工作重心在於推進癌症科研領域的尖端性研究，尋找更有效的癌症預防、診斷和治療方法，並最終治癒所有類型的癌症。

拓展抗癌國際科研網絡

AFCR的國際性科研網絡由癌症科研和藥物開發等領域的關鍵力量組成，包括國際知名的癌症科研領軍人物，頂級癌症研究醫療機構和大型生物製藥公司。這一優勢使得AFCR能夠以其獨特的定位匯集頂尖癌症科研專家，通過運用創新性遺傳學和分子生物學技術來探求亞洲人群罹患癌症的特殊原因，並將世界各地癌症研究的最新技術成果積極應用於亞洲的癌症科研領域。

構建合作平台

AFCR著力於為不同領域的科學家創建和提供交流合作的科研平台。通過促進傑出科學家之間長期穩定的信息溝通，可使有限資源的使用價值最大化，而實驗室中基礎科研成果也將能夠更迅速地轉化為臨床治療方案，為病患帶來更多福音。

增進公眾防癌抗癌意識

AFCR向公眾提供內容詳盡、更新及時的癌症預防和健康生活方式的信息，幫助公眾了解最新的科研成果及其對於有效預防、診斷和治療癌症的重要意義。具備這些知識，可以使人們更有效地對抗癌症。

RESEARCH PROGRAM OVERVIEW

AFCR provides research and development funding to support the most innovative ideas relating to cancer prevention, early diagnosis and treatment.

Advancing Research for Asian Lung Cancer Patients

Professor Tony Mok at The Chinese University of Hong Kong focuses his research on personalized lung cancer treatments for the Asian population. Results from his research are offering new insights into the mystery of how Asian patients with non-small cell lung cancer develop resistance to targeted therapies. With continued research, Professor Mok's team can develop a promising approach to treating Asian lung cancer patients, giving them the best chance for a longer life.

Identifying Biomarkers for Early Detection of Esophageal Cancer


Professor Maria Li Lung at The University of Hong Kong works on identifying "biomarkers" that could be used to detect esophageal cancer earlier or determine those individuals who are at high risk to develop it. A simple blood screening test for early detection of esophageal cancer can be the fruits of her team's research.

A New Tumor Suppressor Gene and Potential Treatment for Colorectal Cancer Patients

Professor Wei Zhang at MD Anderson Cancer Center, USA, together with his collaborators in China, uses the most advanced technologies to confirm that the lack of a tumor suppressor gene in some Asian colorectal cancer patients may explain why their cancer has spread. This tumor suppressor gene can serve as a prognostic indicator to help doctors choose the best treatment approach for their patients. It may also serve as a target for the development of new therapeutics to stop the spread of colorectal cancer.

Developing Novel Therapeutic Strategies for Colorectal Cancer Patients

Dr. Roberta Pang at The University of Hong Kong is developing a minimally invasive blood test that will accurately determine if colorectal cancer patients are at risk for their cancer to spread, or if former patients are at risk for their cancer to return. The test is one of the "next-generation" tools that doctors could use to diagnose and treat cancer at earlier stages.



科研項目概述

*AFCR致力於通過資助創新性癌症研究和藥物開發項目來促進和推動
癌症預防、診斷和治療領域的進步。*

促進針對亞洲人群的肺癌研究

香港中文大學的莫樹錦教授致力於探索專門針對亞洲人群的肺癌個性化治療方案。莫教授及其合作團隊的研究結果對於了解亞洲非小細胞肺癌患者如何對某些標靶治療產生抗藥性提供了新見解。憑藉其持續的創新性研究，莫教授及其科研小組有望開發出更有效的方法治療亞洲非小細胞肺癌患者，使他們的生命得以延長。

鑑定新型生物標誌物用以及早發現食道癌

香港大學的龍李梅瑞教授致力於鑑定食道癌“生物標記物”的研究，並將其應用於食道癌的早期檢測，以及對食道癌高風險人群的確證。其科研團隊的研究成果將有望轉化為一種簡單的臨床血液篩查測試用以及早發現食道癌。

新腫瘤抑制基因治療大腸癌

美國MD Anderson癌症中心的張微教授及其在中國的合作團隊正在使用最先進的技術用以證實一些亞洲結直腸癌患者癌細胞擴散是由於一種重要的腫瘤抑制基因的缺失。這種腫瘤抑制基因不僅可以用作癌症的預後指標來幫助醫生為患者選擇最佳治療方案，還能作為分子靶標用於研發抑制癌症擴散的新型藥物，為患者帶來新的希望。

開發大腸癌治療新方案

香港大學的彭詠枝博士及其合作團隊正在努力開發一種微創的血液測試用以準確判斷大腸癌患者癌症擴散或復發的風險。這種測試是一種“新生代”的工具，它將幫助醫生在癌症早期階段及時診斷和治療患者，從而拯救生命。



RESEARCH PROGRAM OVERVIEW

AFCR funding is specifically focused on cancers that have significant impacts on Asian populations, which include lung, esophageal, colorectal and ovarian cancers.

Overcoming Treatment Resistance in Ovarian Cancer

Professor Wei Zhang is also blazing the path to develop a treatment that fights the developed resistance to standard chemotherapy that many ovarian cancer patients eventually experience. His team of international collaborators has identified a short piece of RNA called microRNA (miRNA) that may be the key to sensitizing the tumor to chemotherapy, overcoming the problem of resistance. With continued success, the miRNA is likely to become a potent new therapeutic tool for ovarian cancer that can overcome the drug resistance and save the lives of women with ovarian cancer.

Finding a New Way of Understanding and Attacking Cancer


Professor Mingjie Zhang and his research team at the Hong Kong University of Science and Technology are focused on understanding how the loss of cell polarity in epithelial cells causes development of various forms of cancer. Cell polarity means that one end of the cell has a different size, shape, or function from the other side, which allows epithelial surfaces to carry out highly

specialized functions. The team will research the protein complexes that help cells become polarized, learn the details of how they work, and understand why mutations that alter their function cause cancer. This important work will lay the scientific groundwork to develop new therapeutic methods for many types of cancer.

New Drugs to Fight Tumor Formation

Normal cell behavior is governed by a hugely complex web of molecular interactions. Cancer can occur when the normal system breaks down. Professor Nancy Ip and her research team at the Hong Kong University of Science and Technology are working to understand the molecular signaling pathways that lead to tumor formation, to identify new targets for treatment, and to develop small-molecule drugs to attack them. Their work holds promise for improving treatment for patients with colorectal cancer, breast cancer, melanoma and other types of cancer.

科研項目概述



我們的科研基金重點支持肺癌、食道癌、大腸癌和卵巢癌等亞洲高發癌症的研究項目。

消除卵巢癌對化療藥物的抗藥性

張微教授同時也在開發一種新型治療方案克服卵巢癌對標準化療藥物產生抗藥性這一很多卵巢癌患者將最終面臨的難題。其國際合作科研小組已經驗明的一小段稱為“微RNA”的核糖核酸序列可能成為增加腫瘤細胞對化療敏感性的關鍵因素。隨著該研究的持續進展，微RNA將有可能成為一種嶄新的治療工具，用以對抗卵巢癌細胞的耐藥性，救助卵巢癌患者的生命。

尋找癌症根源，開發治療癌症新途徑

香港科技大學的張明傑教授及其科研團隊致力於研究並深入了解上皮細胞極性的消失導致多種癌症產生的原因和機理。細胞極性是指細胞的兩端在大小、形狀或功能上有所不同，這種差異賦予了上皮組織特定的生物學功能。研究將集中揭示一些特定的蛋白質複合物幫助細胞產生極性的過

程和具體作用機制，並揭示相關基因突變通過改變這一過程而引發癌症的生物學原理。這項重要的研究有望為開發新型的治療方法，提高多種癌症的療效提供重要的科研基礎。

開發抑制腫瘤形成的新藥

人體細胞內存在著高度複雜的分子信號網絡。細胞的正常功能正是通過這些分子之間的相互作用來進行調控的。當這個系統的正常運作出現問題時癌症就有可能發生。香港科技大學的葉玉如教授帶領其科研小組正致力於深入研究調控細胞代謝過程的複雜的分子信號網絡，確認新的癌症治療靶標，並開發新型小分子抗癌藥物。該研究有望開發出更有效的抗癌療法，為大腸癌、乳癌、和皮膚黑色素瘤等多種癌症的患者帶來治療的新希望。



INTERNATIONAL PARTNERSHIPS ON CANCER RESEARCH

Meanwhile, we place a high priority on promoting synergistic collaboration across scientific disciplines. We encourage leading scientists to work together to accelerate drug development, which will transfer research discoveries to patient-benefiting clinical applications much faster.

Tissue Bank Consortium in Asia (TBCA)

TBCA is a collaboration platform established by the National Foundation for Cancer Research (NFCR) – AFCR’s partner organization in the USA – that aims to promote and facilitate biospecimen-based international cancer research, with the goal of accelerating personalized cancer medicine for many different types of cancer. Since 2007, AFCR has been working in partnership with NFCR in building and developing the consortium.

In recent years, TBCA initiated a research project focusing on “geographic mapping” of the gastric cancer genome using next generation sequencing technology. Gastric cancer is the fourth most common cancer and the second leading cause of cancer death worldwide. It is particularly prevalent in the Asian countries such as Japan, South Korea, and especially China, where half of gastric cancer cases are diagnosed. The TBCA-initiated international collaborative project, which involves leading cancer research experts from 10 public and private partners in both USA and China, is aimed to identify genes that are responsible for gastric cancer and

its metastasis.

The research is already producing valuable new insights. In an initial paper in January 2015 in the *Proceedings of the National Academy of Sciences of the US*, our researchers reported that defects in three cellular signaling pathways (BRCA2, Wnt and PI3-K-ERBB4) might influence the response of gastric cancers to chemotherapy. This is especially exciting, because a number of drugs targeting these pathways are already available, and have been tested in other cancer types such as breast and ovarian cancers. This research suggests that these drugs, when delivered in a personalized way, might benefit patients with gastric cancer as well. This highly successful project represents a critical step towards making personalized medicine a reality for gastric cancer patients.

Partners of this international research collaboration included: Tianjin Medical University Cancer Institute and Hospital (China); The University of Texas MD Anderson Cancer Center (USA); Beijing Genome Institute (China); The Chinese University of Hong Kong (Hong Kong); Emory University School of Medicine



國際合作科研項目概述

與此同時，我們也積極促進不同科研領域的協同合作，鼓勵科研人員通過合作研究加速新藥開發，更快地將科研成果轉化為醫治病人的良方。

亞洲組織庫聯盟

亞洲組織庫聯盟是一個由美國癌症研究基金會（AFCR在美國的合作機構）組建的國際科研合作平台，其宗旨在於促進開展以腫瘤生物樣本為核心的癌症科研合作項目，以加速針對多種類型癌症的個體化醫療進程。早在2007年，亞洲癌症研究基金會就同美國癌症研究基金會合作，開始積極參與亞洲組織庫聯盟的組建和發展。

聯盟在最近幾年開展了一項重要國際合作研究項目，利用新一代基因測序技術對胃癌基因組進行“地理繪圖”。胃癌是全球第四大常見癌症，同時亦是第二大常見的癌症死亡原因。胃癌在日本，韓國等亞洲國家尤為普遍。特別是在中國，其胃癌病例更達全球胃癌總病例的半數之多。該胃癌研究項目由中美10所頂級的癌症科研機構和大型製藥公司共同參與。各方專家開展合作研究，在遺傳和分子學水平進一步揭示胃癌的奧秘。

研究目前已經取得了極具價值的新發現，其科研成果於2015年1月在《美國國家科學院院刊》上發表。研究發現了三個細胞信號轉導通路(BRCA2, Wnt and PI3-K-ERBB4)，其基因缺陷可能是影響胃癌對化療敏感性的的重要因素。令人振奮的是，目前科學家們已經開發出了針對上述基因缺陷的靶向治療藥物，並測試了其針對其他類型的癌症，例如乳癌、卵巢癌等的治療效果。該項研究表明，將這些靶向藥物對胃癌病人進行

“個體化”應用有望獲得療效。該項研究的成功開展使胃癌個體化醫療的實現向前邁出了關鍵的一步。

該項目的合作機構包括：天津醫科大學腫瘤醫院腫瘤研究所（中國）、德克薩斯大學MD Anderson癌症中心（美國）、華大基因（中國）、香港中文大學（香港）、埃默裡大學醫學院（美國）、梅奧醫學中心（美國）、安進公司（美國）、禮



INTERNATIONAL PARTNERSHIPS ON CANCER RESEARCH

(USA); Mayo Clinic (USA); Amgen Inc. (USA); Eli Lilly and Company (USA); AbbVie Inc. (USA); Bristol-Myers Squibb Company (USA); Ludwig Institute for Cancer Research (USA); Ohio State University (USA); The National Foundation for Cancer Research (USA); Asian Fund for Cancer Research (Hong Kong); University of Copenhagen (Denmark); and University of Pittsburgh (USA).

Continued success of this project will positively impact many areas of gastric cancer diagnosis and treatment, saving more lives from this deadly disease.

Accelerating Brain Cancer Research through International Collaborations

Glioblastoma multiforme (GBM) is the most common and deadliest malignant primary brain tumor in humans. AFCR partners with the National Foundation for Cancer Research (NFCR) in the U.S., Beijing Institute for Brain Disorders (BIBD), and Beijing Neurosurgical Institute (BNI) to develop an international collaboration program focused on GBM. The program brings together top research institutions and scientists from China and US to collaborate on GBM research, with the aim of expediting the translation of research discoveries into clinical applications for this deadly disease and accelerating brain cancer research on a global scale. Recently, AFCR has also connected the Chinese Glioma Cooperative Group (CGCG) to this international collaboration platform.

Supporting Traditional Chinese Medicine (TCM)

AFCR believes that TCM is an invaluable resource for modern treatment of cancer and other diseases. In 2006, AFCR became a proud member of the Consortium for Globalization of Chinese Medicine (CGCM), a Hong Kong-based non-profit international organization that promotes the modernization of TCM.

The modern utilization of TCM worldwide is limited, which is mainly due to the lack of high quality evidence-based research to support the claimed benefits of TCM.

Currently, AFCR and the National Foundation for Cancer Research (NFCR) in the US are jointly building an International Center for TCM Research for Cancer Treatment. The Center aims to expand worldwide recognition of TCM's medical functions and benefits, as well as to advance modernization of TCM in cancer treatment.

Researchers with expertise in TCM modernization and application in cancer treatment will be invited to join the Center. These researchers, including Dr. Yung Chi Cheng at the Yale University School of Medicine, US, and Dr. Edward Chu at the University of Pittsburgh Cancer Center, US., will lead preclinical studies on TCM, using highly standardized research materials and protocols, and perform rigorously monitored clinical trials according to the internationally recognized standard, the Good Clinical Practice (ICH-GCP).



國際合作科研項目概述

來公司（美國）、艾伯維（美國）、施貴寶公司（美國）、路德維格癌症研究所（美國）、俄亥俄州立大學（美國）、美國癌症研究基金會（美國）、亞洲癌症研究基金會（香港）、哥本哈根大學（丹麥）、及匹茲堡大學（美國）。

此項胃癌研究項目的持續成功開展將對胃癌的診斷和治療等領域產生積極的影響，為挽救胃癌患者的生命帶來希望。

腦膠質瘤國際合作

腦膠質瘤是最常見且致死率極高的一種腦腫瘤。亞洲癌症研究基金會和美國癌症研究基金會、北京腦病研究所(BIBD)及北京神經外科研究所(BNI)聯手共同成立了一個國際性的腦膠質瘤研究合作項目。該項目將通過構建國際合作平台來促進學術機構與醫藥產業界的合作，推動世界範圍內的腦腫瘤研究並加速科研成果的臨床應用。近期，通過本基金會的努力，中國膠質瘤協作組也加入了該合作項目。


傳統中醫藥癌症治療國際研究中心

AFCR相信傳統中醫藥對於治療癌症等疾病有著不可忽視的價值。早於2006年我們已經加入了設在香港的國際性公益組織“中藥全球化聯盟”，共同致力於推動傳統中醫藥的現代化應用。

傳統中醫藥在世界範圍內的應用卻非常有限，主要原因是傳統中醫藥的療效缺乏高質量的、以實驗數據為依據的、現代科學研究的支持。

為了進一步推動傳統中醫藥的現代化進程，AFCR正在計劃聯手美國癌症研究基金會共同籌集經費以成立傳統中醫藥癌症治療國際研究中心。

中心將由該研究領域的頂尖中國和美國學者主持科學研究，其中包括美國耶魯大學醫學院的鄭永齊博士和匹茲堡大學癌症中心的Edward Chu博士。通過應用高度標準化的科研材料和試驗計劃進行臨床前期試驗研究，並依據國際規範進行嚴格的臨床試驗，該研究中心將力求擴展人們對傳統中醫藥的認知並加速其現代化進程。



RESEARCH DISCOVERIES

Support from AFCR over the past few years has already made possible several notable discoveries led by AFCR scientists, making important steps forward towards curing cancer.

Discovery of the key role for the molecule miR-506 in ovarian cancer – the deadliest cancer of the female reproductive system, by Professor Wei Zhang’s team. While deregulation of miR-506 makes ovarian cancer more aggressive, increasing levels stop cancer cells from growing. This critical finding suggests an entirely new way to treat ovarian cancer - by restoring miR-506 function. Published and featured on the cover of the July 2014 issue of the *Journal of Pathology*.

Discovery of a new combinational treatment approach for ovarian cancer. More recently, Professor Wei Zhang’s team demonstrated that adding miR-506 to standard chemotherapy can help tumor cells overcome drug resistance, which may help solve the notorious problem of chemotherapy resistance in ovarian cancer and increase patient survival. Published in the July 2015 issue of the *Journal of the National Cancer Institute*.

Discovery of an important molecular interaction that appears to be involved in tumor formation and metastasis by Professor Mingjie Zhang’s team. This offers a new potential target for cancer treatment or prevention, which may be effective against many cancer types. Published in the December 2014 issue of the *Proceedings of the National Academy of Sciences*.

Discovery of three key mutations that drive gastric cancer – a leading cause of cancer death in Asia, by an ongoing international collaboration sponsored in part by AFCR. Drugs targeting these mutations are already available, and personalized medicine for gastric cancer patients is on the horizon. Published in the January 2015 issue of the *Proceedings of the National Academy of Sciences*.

重要科研成果概述



幾年來AFCR資助的科研項目已經取得了多項令人欣喜的研究成果，
使我們在治愈癌症的道路上繼續向前邁進。

由張微教授率領的科研團隊近期發現，人體細胞內一種特殊分子miR-506與最致命的婦科惡性腫瘤——卵巢癌密切相關。研究表明，miR-506的失調會使卵巢癌細胞更加具有侵略性，而提高miR-506在細胞內的水平則可阻止癌細胞生長。這一研究結果顯示，修復受損缺失的miR-506可能為卵巢癌患者提供一種新型有效的治療方法。這一科研成果於2014年7月在《病理學》研究期刊上發表，並成為該期期刊的封面文章。

該團隊的最新研究發現了一種治療卵巢癌的新型藥物組合療法。張教授的研究表明，在標準化療藥物中加入miR-506分子能夠有效地降低腫瘤細胞抗藥性，延長化療藥物的治療效果。這一新發現有望解決卵巢癌對化療藥物產生抗藥性的醫學難題，並最終提高患者的生存率。該項科研成果在2015年7月的《美國國立癌症研究所雜誌》發表。

由張明傑教授率領的科研團隊也取得了重大研究成果。該團隊致力於研究超過八成癌症的起源之處——上皮細胞，並發現了一個與腫瘤發生和轉移相關的重要分子作用機制。這項發現有望為開發癌症治療和預防手段提供新的靶標，並有望應用於多種類型的癌症。這一科研成果於2014年12月在《美國國家科學院院刊》上發表。

由AFCR參與並部分資助的一個國際合作項目致力於研究亞洲人群的最致命癌症之一——胃癌。參與該項目的科研人員於近期發現了三個關鍵的胃癌驅動基因。令人振奮的是，目前科學家們已經開發出了針對上述基因缺陷的靶向治療藥物。通過基因學分析，為胃癌病人“私人定制”最佳治療方案的“個體化醫療”已不再是夢想。這一重大科研成果於2015年1月在《美國國家科學院院刊》上發表。



FOSTERING INTERNATIONAL RESEARCH COLLABORATION

AFCR is dedicated to fostering and facilitating scientific discussions and cooperation between Asia and the rest of the world through promoting, coordinating and funding international collaboration in cancer research.

Hong Kong Biotech Horizons Symposium

This event was co-hosted by the Hong Kong Biotechnology Organization (HKBIO) and the Asian Fund for Cancer Research. The symposium invited top local and international experts in the field to be speakers, featuring Professor Roger D. Kornberg, recipient of the Nobel Prize in Chemistry 2006, as the keynote speaker. AFCR scientists Professors Tony Mok and Maria Li Lung also attended the event. The symposium introduced leading-edge achievements in translational research and provided a great platform for scientists to share innovative technology advances and experiences in biotech commercialization.

AFCR-USCACA Scholar Award

Chinese researchers and physicians are being increasingly recognized in making significant contributions to advance research in cancer and other biomedical fields. To facilitate and strengthen collaboration among cancer researchers and physicians in China and US, AFCR and USCACA jointly select five outstanding young

individuals for the award each year, in recognition of their research excellence in basic or clinical cancer research.

Other high-impact international cancer research events supported by AFCR include:

US-Asia Panel Discussion on Targeted Cancer Therapies and Global Strategy for Clinical Development

China-US Symposium on the State-of-the-Art of Cancer Research and Future Directions for Global Collaboration

US-China Workshop on Developing Common Standards for Biorepositories and Biospecimen Research

The 5th Sino-US Conference: Personalized Medicine in Cancer Therapy

International Think-Tank Forums

This type of international collaboration dialogues brings together leading cancer researchers from around the world, shaping the future direction of cancer research on a global scale.

促進國際科研合作



AFCR致力於通過促進、協調和資助在癌症研究方面的國際合作項目，來發展和推動亞洲同世界其它地區之間的交流與協作。

香港生物科技轉化醫學發展研討會

本次研討會由香港生物科技協會（HKBIO）與亞洲癌症研究基金會聯合舉辦。會議邀請到了國內外該領域的頂尖研究人員作為演講嘉賓，包括2006年諾貝爾化學獎得主Roger D. Kornberg教授，以及包括莫樹錦教授和龍李梅瑞教授在內的數位AFCR科學家。本次研討會展示了大中華區和整個亞洲地區現階段在科技轉化研究方面的最新成果，並對該領域在學術界和工業界的進一步發展起到了積極的推動作用。

AFCR-USCACA 優秀學者獎

近年來，中國的臨床醫師和科研人員在腫瘤研究等生物醫學領域做出日益顯著的貢獻並獲得廣泛的認可。為促進和加強中美兩國腫瘤研究的交流與協作，每年AFCR同美中抗癌協會聯合選出在癌


症研究方面取得傑出成績的五名中國青年科學家授予該獎，以表彰他們在基礎或臨床腫瘤研究方面所取得的成績。

AFCR支持的其它具有高影響力的國際癌症研究學術活動包括：

亞美癌症靶向治療和全球性臨床藥物開發戰略專項研討會
中美癌症研究和全球合作發展科學研討會
中美生物樣本研究國際研討會
第五屆中美科學論壇：癌症治療的個體化
抗癌研究與國際合作論壇

這些國際會議促進了全球癌症研究領域專家的學術交流，對癌症研究的未來走向具有重要的指導意義。

A FIGHT AGAINST CANCER THAT'S BEYOND PERSONAL



Mr. Eric Wong (nicknamed “Coffee Wong”), Former Director and General Manager of Bright Sun Coffee Co., Ltd, had “grown up in coffee beans.” With unwavering interest in coffee since childhood, he had become an expert on everything about coffee. In 2013, Mr. Wong published a book “Enjoy Coffee, Enjoy Life” in which he shared all his love and knowledge of coffee with readers – from identification of various brands and tastes of coffee, to ways of grinding and brewing different types of coffee – in the hope that people will learn more about coffee and the joy it brings to life.

The book carried another hope as well. Mr. Wong had been fighting brain tumor for several years prior to the publication, and he hoped that his new book could not only help people enjoy coffee, but also help researchers at AFCR to find new ways against cancer.

On March 23, 2013, Mr. Wong successfully hosted a book signing and charitable donation event for his new book. At the event, Mr. Wong shared his feelings and experiences of writing and publishing this book, and also had a charitable sale for his new coffee flavor “Happy Ha Ha Ha.”

AFCR CEO Dr. Sujuan Ba, Chairman of the Board Mr. Gary Wong, Board Member Ms. Jenny Chan, and CFO Dr. Kwok Leung were present at the book

signing event and talked about AFCR’s mission, focus and current research work in Hong Kong. The event raised more than HK\$45,000 from book sale and coffee sale to benefit AFCR’s innovative cancer research projects that would lead to more advanced and effective diagnostic and treatment approaches for cancer.

Mr. Wong’s battle came to an end in June 2014. However, the extraordinary courage he had demonstrated in the fight against cancer from day one of his diagnosis and his altruistic commitment to cancer research have a long-lasting impact on us all. AFCR thanks Mr. Wong and all his friends for their philanthropic support of life-saving cancer research, and hopes that Mr. Wong’s legacy continues with more people joining AFCR in the fight to accelerate discovery and save more lives.



行動起來，共抗癌症



香港榮陽咖啡有限公司前任董事總經理黃冠樺先生(業內人稱“咖啡黃”)是“在咖啡豆中長大的”。對咖啡一直以來的由衷熱愛使黃先生成為了一名咖啡專家。在2013年，黃先生出版了新書《咖啡黃·嘆咖啡~ 享受咖啡享受人生》與讀者分享他對各種咖啡從識別、鑑賞到研磨、烹煮等方方面面的經驗和感受。黃先生希望通過此書幫助更多的人認識並享受咖啡帶給生活的美好。

黃先生出版此書還另有一份殷切的期望。在此前的幾年中，黃先生同腦瘤一直進行著不懈的鬥爭。他希望通過這本書的義賣幫助亞洲癌症研究基金會籌集研究經費，尋找抗癌良方。

新書簽名會暨慈善義賣於2013年3月23日下午在Safety Stop Café成功舉辦。活動當天，黃先生與讀者們分享了出版本書的點滴，並慈善發售了他新併配的一款取名為“Happy Ha Ha Ha”的咖啡。活動籌得的善款被捐贈予亞洲癌症研究基金會以資助創新性的癌症研究項目，開發更先進、更有效的診斷和治療方法。

亞洲癌症研究基金會首席執行官巴素娟博士、理事會主席黃子寧先生，理事陳幗輝女士及財務總

監梁國維博士出席了當日的新書慈善義賣及簽名會，並介紹了基金會的設立宗旨、工作重心以及在香港的科研項目。此次新書簽名會暨慈善義賣取得了巨大的成功，為亞洲癌症研究基金會的創新性科研項目籌得了45,000多港元的善款。

2014年6月，黃先生的癌症最終不治。然而，他自始至終勇於直面癌症，並在生命的最後階段仍然為癌症科研事業積極籌款的善舉讓我們深為欽佩。我們感謝黃先生和所有參加慈善義賣並積極捐款的朋友，並且衷心希望更多的熱心人士能夠像黃先生一樣與我們共同攜手抗癌，拯救更多的生命。





PUBLIC EDUCATION ON CANCER

AFCR actively communicates the latest breakthroughs in cancer research to the public, ensuring that communities throughout Asia have access to the most updated information on prevention, detection and treatment of all types of cancer.

Monthly E-News

AFCR's free monthly e-newsletters help increase awareness of cancer prevention and early detection. Through this monthly communication, AFCR keeps our supporters and friends informed with the latest cancer research breakthroughs, healthy eating & lifestyle tips, local event opportunities, and more cancer-related information updates.

"On Your Health" Series

AFCR publishes a series of "On Your Health" articles that provide cancer-fighting guidance to help people reduce their cancer risk through lifestyle and diet change.

Cancer Detection Guide

For most types of cancer, early detection is the key to survival. The Cancer Detection Guide compiled by AFCR helps educate individuals about the latest cancer screenings and diagnostic tests for various cancers that may help them detect cancer early.

Prevention Tips for Ovarian Cancer

Ovarian cancer is the most deadly cancer of the female reproductive system, which often goes undiagnosed until after the disease is far advanced. AFCR provides detailed information about risk factors, symptoms and prevention tips for ovarian cancer, aiming to raise more awareness in women of this "Silent Killer."

Skin Cancer Prevention Tips

Studies have shown that much of the skin damage that leads to skin cancer is caused by overexposure to Ultraviolet (UV) rays. AFCR offers practical skin cancer prevention guidelines to help keep people and their families skin cancer-free.

Risk Factors for Colorectal Cancer

Colorectal cancer is one of the leading cancer killers in the Asian population. It is also one of the most preventable cancers. The information AFCR provides is aimed to help the general public better understand the risk factors of the disease so that they can minimize the risk through adopting healthy lifestyles and taking regular colorectal cancer screening examinations.



癌症公眾教育

AFCR 同時致力於癌症的公眾教育，介紹最新的癌症預防策略、癌症早期檢測工具和最新開發的抗癌療法，以使全亞洲地區的人們都能及時獲得針對各類癌症預防、檢測和治療的信息。

電子簡訊

AFCR每月免費寄出電子簡訊，帮助大家增強癌症的預防和早期檢測意識。通過每月一次的聯系，AFCR不斷地知會我們的支持者和朋友們有關癌症研究的新進展、推薦有關健康飲食和生活方式的小常識、以及介紹本地的抗癌活動、並提供及更新與癌症相關的其他信息。

“為您健康”系列

AFCR在“為您健康”專欄中發表文章，以指導公眾通過改變生活方式和飲食習慣來降低罹患癌症的風險。

癌症檢測指南

對於大多數癌症來說，早期檢測是存活的關鍵。AFCR編譯了癌症檢測指南帮助大家了解癌症的預警徵兆，使得早期檢測成為可能。

卵巢癌風險因素及預防建議

卵巢癌是女性生殖系統最致命的癌症。經常是癌症發展到後期才被確診。AFCR向公眾提供卵巢癌的風險因素、症狀和預防建議，以增強女性對這一“無聲殺手”的認知。

皮膚癌預防指南

有研究表明，導致皮膚癌的皮膚損傷很大部分是因過度暴露於紫外線（UV）照射所致。AFCR向公眾提供有效可行的皮膚癌預防指南，幫助人們更有效地保護自己和家人在日常生活中免受皮膚癌危害。

大腸癌風險因素簡介

大腸癌是亞洲人群的主要癌症殺手之一，同時也是最可預防的一種癌症。AFCR提供相關信息來幫助公眾更好地認識大腸癌的風險因素，並通過調整生活習慣和定期接受篩查更好地預防大腸癌。

PUBLIC EDUCATION ON CANCER



Breast Cancer Examination

The earlier breast cancer is diagnosed, the better the chance of recovery. AFCR provides the latest guidance about periodic self-examination and screening that may help detect breast cancer early and save life.

Risk Factors for Lung Cancer

Lung cancer is another highly preventable cancer type that largely impacts the Asian population. AFCR provides the general public with risk factors for this disease and encourages people to live a healthy lifestyle, which is crucial for lung cancer prevention.

Warning Signs of Cancer

Knowing the warning signs of cancer may help detect cancer early and treatment the disease more successfully. We have put together warning signs of a variety of cancers such as lung, breast, colorectal, prostate, uterine, ovarian, cervical, and skin cancer.

Cancer-Fighting Recipes

Food with cancer-fighting properties help reduce the risk of many cancers. We have put together a wide variety of healthy recipes, from traditional to new and interesting ones, to help people add more healthy foods to their daily diet.

Cancer Awareness Colors

There are many forms of cancer and each presents its challenges and mysteries. AFCR has put together ribbons which symbolize a variety of cancer types. Our goal is to increase public awareness of various cancers and to understand cancer at the cellular and molecular level—understanding the root causes of cancer.

Childhood Cancer Detection Chart

Survival rates among children with cancer have significantly improved over the past 30 years, thanks to advances in cancer research and treatment. However, cancer still ranks as the second leading cause of death for all children ages 1-14. AFCR has put together all the necessary information for childhood cancer detection in one chart to help parents understand the different types of cancer, such as leukemia and lymphoma, and how to detect any symptoms of those diseases in their own children.



癌症公眾教育

乳癌檢測方法指南

乳癌愈早確診，愈可能被治癒。AFCR提供最新的乳房定期自查和臨床篩查指南以幫助女性及早發現癌症。

肺癌風險因素簡介

肺癌是另外一種對亞洲人群有重大影響並在很大程度上可以預防的癌症。AFCR向公眾提供肺癌風險因素簡介並鼓勵人們採取健康的生活方式，預防肺癌。

常見癌症初期症狀

對常見癌症初期症狀的了解能夠幫助人們及早發現癌症，增加治療的成功率。因此我們匯集了各種癌症的初期症狀，包括肺癌、乳癌、大腸癌、前列腺癌、子宮癌、卵巢癌、宮頸癌、和皮膚癌。

抗癌食譜

每天攝入抗癌食品可以降低罹患癌症的風險。AFCR準備了大量不同類型的健康食譜，有傳統

的，也有新鮮有趣的，幫助您將更多的健康食品擺上餐桌。

癌症關注色彩表

癌症有很多種類型，每一種類型都給癌症科研帶來新的挑戰。我們收集了代表不同癌症的色彩圖，製作了癌症關注色彩表。我們的目標是提高公眾對癌症的認知和關注，以便更好地防癌抗癌。

兒童癌症檢測表

癌症研究和治療方法的進步使兒童癌症患者的生存率在過去的30年中有了顯著的提高。然而，癌症仍然被列為1-14歲兒童死亡的第二大原因。AFCR已將兒童癌症檢測的相關信息彙集成表格來幫助家長們了解兒童癌症的不同類型，例如白血病和淋巴瘤，並告訴他們如何發現出現在自己孩子身上的相關症狀。

BOARD OF DIRECTORS 理事會

Gary Gee Nung Wong, Chairman 黃子寧, 主席
OLN Lawyers 高李嚴律師行

Jenny Kwok Fai Chan 陳楓輝
The Family Planning Association of Hong Kong
香港家庭計劃指導會

Albert Cheung-Hoi Yu, Ph.D. 于常海教授
Hong Kong Biotechnology Organization
Hai Kang Life Corporation Limited
香港生物科技協會 海康生命科技有限公司

SCIENTIFIC ADVISORY BOARD 科學顧問委員會

Webster Cavenee, Ph.D. Chairman 主席
Ludwig Institute for Cancer Research
美國Ludwig癌症研究所

Anthony Chan, M.D. 陳德章教授
The Chinese University of Hong Kong
香港中文大學

Yung-Chi Cheng, Ph.D. 鄭永齊教授
Yale University School of Medicine
美國耶魯大學醫學院

Mien-Chie Hung, Ph.D. 洪明奇教授
University of Texas MD Anderson Cancer Center
美國德州大學 MD Anderson 癌症中心

Paul Schimmel, Ph.D.
Scripps Research Institute
美國斯克里普斯研究所

George Tsao, Ph.D. 曹世華教授
The University of Hong Kong
香港大學

MEDICAL ADVISORY BOARD 醫學顧問委員會

Ronnie Poon, MBBS, MS, Ph.D. Chairman
潘冬平教授, 主席
The University of Hong Kong and Queen Mary Hospital
香港大學及瑪麗醫院

Edward Chu, M.D.
University of Pittsburgh
美國匹斯堡大學

Waun Ki Hong, M.D.
University of Texas MD Anderson Cancer Center
美國德州大學 MD Anderson 癌症中心

Tony S. K. Mok, M.D. 莫樹錦教授
The Chinese University of Hong Kong
香港中文大學

Ben Yong, M.D. 黃勇博士
Pfizer Global Research and Development
輝瑞製藥公司全球研究開發

Wai-Kwan Alfred Yung, M.D.
University of Texas MD Anderson Cancer Center
美國德州大學 MD Anderson 癌症中心

Yifan Zhai, M.D., Ph.D. 翟一帆博士
HealthQuest Pharma Inc.
廣州順健生物醫藥科技有限公司



**ASIAN FUND FOR
CANCER RESEARCH**
亞洲癌症研究基金會

www.AFCR.org.hk | contact@afcr.org.hk

Hong Kong Office 香港辦公室
5/F Dah Sing Life Building, 99-105
Des Voeux Road Central, Hong Kong
香港中環德輔道中99-105號
大新人壽大廈五字樓
Tel 電話: 2156 9684
Fax 傳真: 2156 9685

U.S. Office 美國辦公室
4600 East West Highway, Ste 525
Bethesda, MD 20814 USA
Tel 電話: 1-301-961-9131
Fax 傳真: 1-301-654-5824

